Funding for Faculty

Siteman Funding Opportunities Newsletter

Download the Latest Siteman Funding Opportunities Newsletter (PDF)

The newsletter and the list of open opportunities on this page are not fully inclusive of all available cancer-related funding. Please be sure to consult other sources to learn of other opportunities not listed here.

May Deadlines

May 20: DEADLINE EXTENDED: Drug Repurposing Clinical Trials to Impact Blood Cancers – Cures Within Reach

Additional Details

RFP Snapshot: This RFP is seeking repurposed treatments to address unsolved blood cancers. We are interested in generic or proprietary drugs that could be repurposed to create “”new”” treatments to 1) reduce the symptoms, progression or incidence of; 2) restore function lost to; or 3) reduce or eliminate severe side effects of currently used therapies for any blood cancer, thereby improving patient outcomes and quality of life.

Max Amount and Period: $75,000 over 3 years (includes 20% institutional match)

Eligibility: The strongest preference is for proof of concept repurposing clinical research trials supported by strong preclinical evidence and / or clinical observations. We may also consider later stage clinical trials that require additional funding if our additional funding will help speed the patient impact of the clinical trial. Only interventional clinical trials lasting no more than 36 months that treat patients with a repurposed therapy are eligible for this funding. Eligible clinical repurposing trials may also a) test combination therapies to increase their efficacy, including combining the current disease treatment with a repurposed treatment or combining multiple repurposed therapies or b) repurpose therapies approved for use in adults into pediatric indications, or vice versa.

Due Date: May 20, 2022 at 10:59PM CST

May 26: LOI: Quality of Care Initiative to Improve the Treatment of Advanced or Metastatic Bladder Cancer Patients – NCCN, Pfizer, and EMD Serono

Additional Details

RFP Snapshot: The intent of the RFP is to encourage NCCN Member Institutions and non-NCCN Member Institutions to submit letters of intent (LOIs) describing concepts and ideas around how to improve the quality of care, including guideline concordant care, and best practices around treatment for patients with Metastatic or Advanced Bladder Cancers. A successful project will incorporate quality improvement methods to overcome identified barriers to improve care. These barriers include, but are not limited to, identifying clinical and treatment related factors, patient-related psychosocial factors and healthcare system or technological related barriers.

Max Amount and Period: $300,000 over 2 years

Eligibility: PIs from academic centers are encouraged to include a co-investigator from the community.

Due Date: Letter of Intent Due: May 26, 2022 at 10:59PM CST

May 26 LOI: Quality of Care Initiative to Improve the Treatment of Advanced or Metastatic Bladder Cancer Patients Request for Proposals

Additional Details

RFP Snapshot: The intent of the RFP is to encourage NCCN Member Institutions and non-NCCN Member Institutions to submit letters of intent (LOIs) describing concepts and ideas around how to improve the quality of care, including guideline concordant care, and best practices around treatment for patients with Metastatic or Advanced Bladder Cancers. A successful project will incorporate quality improvement methods to overcome identified barriers to improve care. These barriers include, but are not limited to, identifying clinical and treatment related factors, patient-related psychosocial factors and healthcare system or technological related barriers.

Max Amount and Period: $300,000 over 2 years

Eligibility: PIs from academic centers are encouraged to include a co-investigator from the community.

Due Date: Letter of Intent Due: May 26, 2022 at 4PM CST

May 27 LOI: LCRF Minority Career Development Award (CDA) in Lung Cancer

Additional Details

RFP Snapshot: The intent of this Request for Proposal (RFP) is to support early-stage scientists from underrepresented groups working in lung cancer and working in diverse areas of research including basic, clinical, translational, disparities, and social determinants of health research.

Max Amount and Period: $150,000 over 2 years

Eligibility: Investigators must be from racial or ethnic groups that are underrepresented in health-related sciences and biomedical research. Applicants must be postdoc researchers, clinical fellows, or early- to mid-career investigators within 10 years of receiving their MD and or PhD. Applicants are prohibited from applying if they have received funding from the LCRF within the last 4 years.

Due Date: Letter of Intent Due: May 27, 2022 at 10:59PM CST

May 31: LOI: 2022 AA MDSIF Research Grants – Aplastic Anemia and MDS International Foundation

Additional Details

RFP Snapshot: The purpose of this RFA is to help researchers dedicated to the study of bone marrow disorders, advance the understanding, prevention and treatment of the following disorders for both pediatric and adult populations: aplastic anemia, MDS, MPN, CMML, PNH, PRCA. The 2022 program will accept applications in any of the following research areas: basic, translational, pre-clinical, early-stage clinical, or health services.

Max Amount and Period: $60,000 over 2 years

Eligibility: To be eligible to apply for a research grant, an applicant must hold a Doctor of Medicine, Doctor of Philosophy, Doctor of Osteopathy, Doctor of Science, or other doctoral level degree (e.g., PharmD). There are no nationality restrictions. The project must represent independent research conducted by the applicant. Members of the AAMDSIF Scientific and Medical Advisory Board are not eligible to apply for a grant, and may sponsor no more than 1 applicant during any given round. Preference will be given to new investigators* who propose a project that will contribute toward their professional development in bone marrow failure disease research.

Due Date: Letter of Intent Due: May 31, 2022 at 4PM CST

Eligibility Note: *New Investigators include post-doctoral fellows, instructors, and those who have been assistant professors for fewer than five years.

June Deadlines

June 1: Cancer Stem Cell Clinician-Scientist Development Grant – American Cancer Society and Lisa Dean Moseley Foundation

Additional Details

RFP Snapshot: This grant is in connection with the ACS Cancer Stem Cell Consortium and provides protected time for junior faculty to be mentored and participate in cancer stem cell-related research training to aid their development as independent clinician scientists. Please be sure to locate this specific opportunity on the linked webpage.

Max Amount and Period: $675,000 over 5 years

Eligibility: Applicant is eligible to submit if they are a licensed clinician within the first 6 years of the initial faculty appointment and have an active role in patient care.

Due Date: June 1, 2022 at 10:59PM CST

June 1: Cancer Stem Cell Research Scholar Grant – American Cancer Society and Lisa Dean Moseley Foundation

Additional Details

RFP Snapshot: This grant is in connection with the ACS Cancer Stem Cell Consortium and funds an independent research project related to cancer stem cells. Please be sure to locate this specific opportunity on the linked webpage.

Max Amount and Period: $660,000 over 4 years

Eligibility: Applicant is eligible to submit if they are a full-time independent investigator at any stage and have any level of extramural funding.

Due Date: June 1, 2022 at 10:59PM CST

June 1: Leukemia Research Grants – When Everyone Survives (WES) Leukemia Research Foundation

Additional Details

RFP Snapshot: This request for proposals (RFP) is offered by the When Everyone Survives Foundation (WES Leukemia Research Foundation) to solicit innovative research in leukemia. The WES Foundation supports leukemia research because it recognizes that significant advances in the understanding, diagnosis, and treatment of leukemia are needed to achieve the goal of “When Everyone Survives”. Anticipated award start date is October 1, 2022.

Max Amount and Period: $50,000 for 1 year

Eligibility: Applicants can be new or established investigators who are requesting support for laboratory, translational, or clinical research related to acute leukemia.

Due Date: June 1, 2022 at 10:59PM CST

June 6: LOI: Cancer Control Research in Persistent Poverty Areas (U54 Clinical Trial Optional) – NIH/NCI

Additional Details

RFP Snapshot: The goal of this U54 is to provide resources to support the time and effort of transdisciplinary teams, in collaboration with institutions, clinics, and communities/tribes, to develop a cancer prevention and control research program and provide support to early-career investigators that focuses on and serves populations living in persistent poverty areas. All proposed Centers must include the following components: Administrative Core, Research and Methods Core, Career Enhancement Core, Developmental Core, and Research Projects.

Max Amount and Period: $7.5M over 5 years

Eligibility: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Due Date: Letter of Intent Due: June 6, 2022 at 5PM CST

June 6: U.S.-Based Clinical Repurposing Trials to Address Diversity, Equity, and Inclusion – Cures Within Reach

Additional Details

RFP Snapshot: This RFP is seeking clinical repurposing trials from US-based Principal Investigators (PIs) to address DEI in clinical research. Trials proposed must be interventional, using repurposed therapies, including drugs, devices, nutraceuticals, and diagnostics. Clinical trials utilizing telehealth or other remote strategies are encouraged to apply. Any health disparities submissions for this RFP must include ideas and/or plans for engagement / collaborations with community-based organizations to engage communities of color in the clinical trial.

Max Amount and Period: $70,000 over 3 years (includes 20% institutional match)

Eligibility: Eligible submissions must EITHER be led by a US-based underrepresented racial / ethnic minority PI OR address rare disease racial / ethnic health disparities in communities of color as defined by the NIH.

Due Date: June 6, 2022 at 10:59PM CST

June 9: Eligibility Checklist: Early Career Investigator Award – Colorectal Cancer Alliance

Additional Details

RFP Snapshot: Early Career Investigator Awards aim to attract early career faculty with original ideas into the field of colorectal cancer research, thereby recruiting and supporting the next generation of CRC research leaders. Awardees will be provided funding to accomplish innovative and original, preclinical, translational, and/or early clinical research projects. Early Career Investigators are defined as scientists within the first five years of their first academic faculty appointment. A mentorship commitment from a senior investigator is required.

Max Amount and Period: $150,000 over 2 years

Eligibility: Applicants must be within the first five years of their first independent, full-time academic faculty appointment and at the level of Assistant Professor or equivalent. Applicants must designate at least one mentor who is an established investigator.

* The eligibility checklist is available for download on proposalCENTRAL. You will need to click “Apply Now” next to the opportunity, fill out the title and amount requested, and then the checklist will be available on the “Download Templates and Instructions” page.

Due Date: Eligibility Checklist Due: June 9, 2022 at 4PM CST

June 13: Diversity in Early Development Clinical Trials – Stand Up To Cancer

Additional Details

RFP Snapshot: The objective is to increase accessibility for patients of all racial and ethnic backgrounds and/or medically underserved locations to equally participate in studies that will lead to breakthroughs in cancer treatments that may benefit all patients.

Max Amount and Period: $550,000 over 2 years

Eligibility: Being mindful of existing barriers to participation in research, the selected grantee Teams will demonstrate the ability to develop new approaches to address health disparities in the context of Phase 1 and Phase 2 cancer research and obtain comparable outcomes for all racial and ethnic populations.

Due Date: June 13, 2022 at 12 Noon CST

June 15: LOI: Neurofibromatosis Type 1 (NF1) Gene Therapy Initiative – Children’s Tumor Foundation

Additional Details

RFP Snapshot: The Children’s Tumor Foundation (CTF) neurofibromatosis type 1 (NF1) Gene Therapy Initiative

is requesting applications for projects exploring gene therapy approaches to treating NF1 plexiform neurofibromas (pNF) and/or malignant peripheral nerve sheath tumors (MPNST). Investigators should describe and provide rationale for the target(s), therapeutic molecules, method(s) of therapy delivery, outcome measures to evaluate success and off-target effects, feasibility, and applicability among NF1 patients. All approaches will be considered. Innovation using newest approaches to optimize success while minimizing risk will be viewed particularly favorably.

Max Amount and Period: $330,000 over 2 years – optional third year of funding available if well-justified

Eligibility: Applicant should have a MD, PhD, or equivalent, with an established record of independent research, and must have full access to, or identified collaborators with, all required resources. Investigative groups should not only contain expertise in the strategy and tumor therapeutics, but familiarity with NF1.

Due Date: Letter of Intent Due: June 15, 2022 at 4PM CST

June 15: LOI: ACS Screening/Early Detection Interdisciplinary Team Award – American Cancer Society

Additional Details

RFP Snapshot: This award funds team science to advance cancer screening and early detection. All Team Award applications must clearly articulate how the team will synergize to accelerate scientific advancement and clinical benefit. The ACS defines an interdisciplinary team as one having well-justified representation of diverse research skills and perspectives, not merely team members representing different departments.

Max Amount and Period: $1,200,000 over 5 years

Eligibility: Interested applicant teams must have a lead PI, a team principal, and at least one team investigator. The lead PI must have been a full-time independent investigator for at least 5 years and has the ability to dedicate 10% or more of their time and effort to the team project.

Due Date: Letter of Intent Due: June 15, 2022 at 10:59PM CST

June 15: Enzo and Me Pediatric Cancer Foundation Grant for Rhabdomyosarcoma Research – Children’s Oncology Group Foundation

Additional Details

RFP Snapshot: Dedicated funding to support pediatric rhabdomyosarcoma research.

Max Amount and Period: $50,000 for 1 year – potential second year of funding available if justified

Eligibility: Any interested investigator with the applicable expertise and experience. Must become a COG individual member if awarded.

Due Date: June 15, 2022 at 10:59PM CST

June 15: Enzo and Me Pediatric Cancer Foundation Grant for Osteosarcoma Research – Children’s Oncology Group Foundation

Additional Details

RFP Snapshot: Dedicated funding to support pediatric osteosarcoma research.

Max Amount and Period: $50,000 for 1 year – potential second year of funding available if justified

Eligibility: Any interested investigator with the applicable expertise and experience. Must become a COG individual member if awarded.

Due Date: June 15, 2022 at 10:59PM CST

June 16: Transformative Cancer Research Grants – AACR and MPM Oncology Charitable Foundation

Additional Details

RFP Snapshot: This RFP is a joint effort to stimulate “high-risk, high-reward” research from early- to mid-career investigators. This grant mechanism is intended to promote and support creative, paradigm-shifting cancer research that might not be funded through conventional channels. It is expected that these grants will catalyze significant scientific discoveries that will advance our understanding of cancer and have a potentially transformative impact on future clinical practice. The proposed research must represent a highly innovative approach to a major problem or challenge in cancer research. The funded projects are expected to catalyze important advances in cancer research, and should have a potentially transformative impact on future clinical practice. The research can be in any area of basic, translational, or clinical research.

Max Amount and Period: $400,000 over 2 years

Eligibility: Applicants must have a doctoral degree (PhD, MD, MD/PhD, or equivalent) in a related field and not currently be a candidate for a further doctoral degree. Candidate must hold an appointment at the rank of Assistant or Associate Professor as of December 1, 2022. No citizenship requirements. Applicants must be AACR Active members. Nonmembers can apply for membership online.

Due Date: June 16, 2022 at 12 Noon CST

June 20: LOI: PCF TACTICAL Team Award – Prostate Cancer Foundation

Additional Details

RFP Snapshot: PCF seeks high-risk, currently unfunded projects from academic institutions around the world that will specifically address the development of 21st Century therapies for lethal forms of prostate cancer. These awards will be funded depending on the level of innovation in applications received. General areas of interest include (but are not limited to): targeting currently undruggable driver transcription factors, new mechanisms for inducing cancer cell death including gene and cell therapies, integrating understanding of therapeutic resistance into up-front treatments, etc.

Max Amount and Period: $5M to $10M over 3 years

Eligibility: Teams must be composed of at least five (5) investigators, including two young investigators, capable of providing unique scientific expertise to the solution of this significant problem in prostate cancer research. Team members must represent a minimum of four (4) non-profit academic research institutions. The young investigators may hold the title of Postdoctoral Fellow, Instructor, Research Associate, Assistant Professor, or equivalent and should be within six years following completion of a professional degree or subsequent mentored academic or clinical training program. They each should not have been granted commitments for more than $500,000 in direct research funding from all sources including institutional funds at the time of this application.

Due Date: Letter of Intent: June 20, 2022 at 2PM CST

June 24: 2022 Research Fellow Award – Multiple Myeloma Research Foundation

Additional Details

RFP Snapshot: This is an initiative supporting early career researchers at the post-doctorate, medical fellow, or junior faculty levels currently active or interested in research in multiple myeloma. The goal of this initiative is to engage and support early career investigators interested in basic and clinical research focused on multiple myeloma and its precursor conditions, with the goal of advancing our understanding of myeloma disease biology, disease risk, and treatment response and relapse. The proposed research must be in a) host immunity in multiple myeloma, b) disease monitoring – immune biomarkers of progression and treatment response, c) disparity research, or d) innovative data solutions.

Max Amount and Period: $150,000 over 2 years

Eligibility: Applicants must have a doctoral degree (PhD, MD, MD/PhD, or equivalent) in a related field and must have obtained their highest degree within 10 years of the application date. Applicants may not hold a position higher than Assistant Professor. Postdoc and medical fellow applicants must be working under the supervision of a research mentor in the multiple myeloma field.

Due Date: June 24, 2022 at 10:59PM CST

June 27: LOI: SU2C Gastroesophageal Cancer Dream Team – Stand Up To Cancer and Torrey Coast Foundation GEMINI Network

Additional Details

RFP Snapshot: The Dream Team represents an unprecedented opportunity to bring together the best scientific minds from diverse fields of research to concentrate on approaches that will bring new therapies to the clinic for the treatment of gastroesophageal cancer. Applications are encouraged from researchers who propose approaches or screens to identify new cancer cell intrinsic therapeutic targets, to target the tumor microenvironment, to utilize new cellular therapies (including NK cell based therapies) or to investigate resistance to immunotherapy in gastroesophageal cancer. A path to clinical trials should be described although initiation of a clinical trial is not required during the span of the Dream Team grant.

Max Amount and Period: $6M over 4 years

Eligibility: The Dream Team must include members with a highly multi-disciplinary range of expertise, perhaps including gastroesophageal cancer sciences, laboratory sciences, biostatistics, and clinical sciences, with senior and early-career investigators, some of whom have not worked together in the past. The Team will consist of a Team Leader, a Team Co-Leader, and at least one Team Principal. One of these three leaders will be new to gastroesophageal cancer research or treatment and will not have previously worked in the field of gastroesophageal cancer. Additionally, one of the these three leaders must have experience with clinical trials. There will be no more than four additional Team Principals, a Project Manager, and at least two Patient Advocates, with a minimum of three participating institutions. Racial and ethnic diversity among Dream Team personnel is strongly encouraged.

Due Date: Letter of Intent: June 27, 2022 at 10:59PM CST

June 28: Victoria’s Secret Global Fund for Women’s Cancer Career Development Award – American Association for Cancer Research (AACR) and Victoria’s Secret

Additional Details

RFP Snapshot: The intent of this Request for Proposal (RFP) is to fund innovative research projects in breast and gynecologic cancers and to invest in the next generation of female early-stage scientists domestically and globally. The aim of this award is to foster innovation in the understanding, prevention, interception, early detection, diagnosis, and treatment of breast and gynecologic cancers with the goal of eliminating cancer health disparities and improving patient outcomes. The research proposed for funding may be in basic, translational, clinical, or population sciences.

Max Amount and Period: $206,000 over 2 years

Eligibility: The PI should be a female investigator with a PhD, MD, MD/PhD, or equivalent, and not be a candidate for a further doctoral degree. Applicants must hold a title of Assistant Professor (Research Assistant Professor, Adjunct Asst. Professor, and Assistant Professor Research Track are also eligible). Applicants that have progressed to Associate Professor or equivalent are NOT eligible.

The applicants must also have completed their most recent doctoral degree within the past 11 years and must devote at least 75% of their total effort to research in breast or gynecologic cancer.

Applicants must be AACR members. Nonmembers interested in this opportunity may apply for AACR membership here. See full RFP (link below) for full eligibility details.

Due Date: June 28, 2022 at Noon CST

June 30: Equity in Access to Cancer Cachexia Clinical Trials – Pfizer Global Medical Grants

 Additional Details

RFP Snapshot: Projects that will be considered for Pfizer support will focus on supporting initiatives to improve identification and equity in access to cancer cachexia clinical trials. It is our intent to support quality improvement projects. It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.

Max Amount and Period: $100,000 – PI specifies project timeline

Eligibility: If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.

Due Date: June 30, 2022 at 10:59PM CST

July Deadlines

July 6: Damon Runyon-Rachleff Innovation Award – Stage 1

Additional Details

RFP Snapshot: This award is designed to provide support for the next generation of exceptionally creative thinkers with “high-risk/high-reward” ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. The proposed research may be a basic or translational/clinical project.

Max Amount and Period: $400,000 over 2 years – with an opportunity for up to two additional years of funding.

Eligibility: The applicant must have a doctoral degree (PhD, MD, DO, or MD/PhD degree and belong to one of the following categories: a) tenure-track Assistant Professors, b) Clinical Instructors and Senior Clinical Fellows, or c) Distinguished Fellows. Applicants must commit a minimum of 80% of their time to conducting research. There is no citizenship requirement. Research Assistant Professors, Research Associate Professors, Research Scientists, and Postdoctoral Fellows are not eligible to apply. Applicants with a background in multiple disciplines are especially encouraged to apply.

Due Date: July 6, 2022 at 3PM CST

July 11: Prevent Cancer Prevention and Early Detection Grants

Additional Details

RFP Snapshot: An eligible proposal must be original and clearly describe pre-clinical, translational, clinical or population-based research projects in the field of cancer prevention or early detection. If successful, research projects reduce the frequency of epithelial neoplasms: e.g., brain, head and neck, lung, breast, prostate, uterus, cervix, ovary, esophagus, stomach, colon, pancreas, liver, skin (including melanoma), HPV-related cancers or hematologic malignancies.

Prevent Cancer highly encourages proposals focused on melanoma prevention and early detection.

Max Amount and Period: $100,000 over 2 years

Eligibility: This award is generally for early-career researchers at the Instructor or Assistant Professor level but can be awarded to post-doctoral level applicants and senior researchers who need seed funding to evaluate an innovative cancer prevention or early detection hypothesis.

Due Date: July 11, 2022 at 10:59PM CST

July 13: Endeavor Award – The Mark Foundation for Cancer Research

Additional Details

RFP Snapshot: These grants are awarded to teams of three or more investigators to generate and integrate data from diverse lines of research and transform those insights into advances for cancer patients that could not be achieved by individual efforts. Research projects may be basic, translational, or clinical and must seek to address an overarching, urgent scientific question. They must not be supported by other sources of funding.

Max Amount and Period: $3M over 3 years

Eligibility: The PI must have an independent faculty research appointment (tenure-track or equivalent). There are no restrictions on citizenship or geography. Investigator teams may comprise investigators from a single institution or multiple institutions. Teams must be composed of one PI, and between 2-8 co-PIs (see “Team Roles” section for definitions).

Due Date: July 13, 2022 at 10:59PM CST

Application Assistance Note: For assistance with reviewing/editing your LOI, Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at floydg@wustl.edu.

July 14: Tobacco Centers of Regulatory Science (TCORS) for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (U54 Clinical Trial Optional) – NIH/NCI

Additional Details

RFP Snapshot: The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for Tobacco Centers of Regulatory Science (TCORS) to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the Research Objectives related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). View pre-recorded, pre-application webinar here: https://prevention.nih.gov/tobacco-regulatory-research/funding-opportunities/pre-application-webinar-tobacco-centers-regulatory-science-tcors

Max Amount and Period: $20M over 5 years ($4M max/year)

Eligibility: The Center PD(s)/PI(s) should be (an) expert(s) in tobacco research, with, at minimum, R01- equivalent research experience, and ideally with experience successfully leading large multi-disciplinary Research Projects. The PD(s)/PI(s) should make substantial time and effort commitments and demonstrate capability to coordinate/collaborate within the proposed Center (that is, across the Center components) and across the TCORS program (that is, among the Centers funded under this FOA, as well as a coordination center and NIH and FDA staff).

Due Date: July 14, 2022 at 5PM CST

July 19: Caroline Craig Augustyn and Damian Augustyn Award in Digestive Cancer – American Gastroenterological Association

Additional Details

RFP Snapshot: The objective of this AGA Research Foundation award is to provide supplemental funding to early career investigators who have existing career development awards and are conducting research relevant to the pathogenesis, prevention, diagnosis or treatment of digestive cancer.

Max Amount and Period: $40,000 for 1 year

Eligibility: Candidates for this award must hold an MD, PhD and/or equivalent degree and hold a full-time faculty appointment as an early-career researcher (less than seven years have elapsed since completion of training). Applicants must hold an NIH K series (e.g., K01, K08, K23, K99, R00) or other federal or non-federal career development award of at least four years’ duration. There must be at least one year remaining on the award on Jan. 1, 2023. Applicants may not hold an R01 or equivalents such as a VA Merit award. Applicant must be an AGA member.

Due Date: July 19, 2022 at 10:59PM CST

July 19: R. Robert and Sally Funderburg Research Award in Gastric Cancer – American Gastroenterological Association

Additional Details

RFP Snapshot: The objective of this AGA Research Foundation award is to support an established investigator in the field of gastric cancer research working to enhance our fundamental understanding of gastric cancer pathobiology or approaches to prevent, treat or cure gastric cancer.

Max Amount and Period: $100,000 over 2 years

Eligibility: Candidates for this award must hold an MD, PhD and/or equivalent degree and hold a full-time faculty appointment as an established investigator (seven or more years have elapsed since completion of training). Applicant must be an AGA member.

Due Date: July 19, 2022 at 10:59PM CST

July 25: Pilot Award – Colorectal Cancer Alliance

Additional Details

RFP Snapshot: Pilot Awards support senior investigators who propose potentially transformative ideas that do not have extensive preliminary data but articulate a clear hypothesis and translational goals. Resources for such “high-risk, high-reward” projects are important to establish proof-of-concept, which may then leverage additional funding through more traditional avenues.

Max Amount and Period: $100,000 over 2 years

Eligibility: Applicants must be hold a full-time faculty appointment at the level of Assistant Professor (or equivalent) or above and be past the initial five years of their first appointment.

Due Date: July 25, 2022 at 4PM CST